Subtrochanteric/Diaphyseal | Transverse or Short Oblique | Associated with Prolonged Antiresorptive Therapy
ASBMR MAJOR CRITERIA (4 of 5 Required)
Critical Must-Knows
- ASBMR criteria define atypical fractures - learn the 5 major features
- Bisphosphonate use greater than 5 years significantly increases risk
- Check contralateral femur - 28% bilateral, may be prodromal
- Drug holiday consideration after complete fracture
- IM nail preferred - allows prophylactic fixation of contralateral
Clinical Pearls
- "Prodromal thigh pain in 70% - often for weeks/months before fracture
- "Lateral cortex stress reaction is pathognomonic on X-ray
- "Risk-benefit still favors bisphosphonates in most osteoporotic patients
- "Glucocorticoid use and Asian ethnicity increase risk
Clinical Imaging
Imaging Gallery


Critical Atypical Femoral Fracture Exam Points
ASBMR Criteria
4 of 5 major criteria must be present for diagnosis. Location (subtrochanteric/diaphyseal), transverse/short oblique pattern, minimal trauma, non-comminuted, lateral cortex beaking. Know these criteria.
Prodromal Symptoms
70% have prodromal thigh pain for weeks to months before complete fracture. This is a missed opportunity for prophylactic treatment. Any patient on bisphosphonates with thigh pain needs imaging.
Check Contralateral
28% have bilateral involvement. Always image the contralateral femur. May be prodromal (incomplete fracture) requiring prophylactic fixation. Same surgery session if complete and prodromal.
IM Nail Preferred
Intramedullary nail is preferred fixation. Allows load-sharing, protects entire femur, enables prophylactic fixation of contralateral. Avoid lateral plate alone (stress riser at plate end).
Atypical Femoral Fracture Management Algorithm
| Presentation | Key Action | Treatment |
|---|---|---|
| Complete atypical fracture | Confirm ASBMR criteria, image contralateral | IM nail fixation, consider drug holiday |
| Incomplete fracture (prodromal) | Protected weight bearing, serial imaging | Prophylactic IM nail if progression or persistent pain |
| Thigh pain on bisphosphonates | X-ray and MRI if X-ray negative | Stop bisphosphonate, calcium/vitamin D, monitor |
| Bilateral involvement | Stage surgery or fix both at same session | IM nail both femurs |
| Post-fracture bone health | Drug holiday vs alternative agent | Endocrinology referral, fracture liaison service |
ASBMR - MASBMR - Major Criteria
| A | Atraumatic (minimal/no trauma) Fall from standing height or less |
| S | Subtrochanteric or shaft Distal to lesser trochanter to supracondylar flare |
| B | Beaking of lateral cortex Periosteal stress reaction |
| M | Minimal comminution Non-comminuted or minimal |
| R | Right angle (transverse/short oblique) Less than 30 degrees obliquity |
| A | Atraumatic (minimal/no trauma) Fall from standing height or less | M | Minimal comminution Non-comminuted or minimal |
| S | Subtrochanteric or shaft Distal to lesser trochanter to supracondylar flare | R | Right angle (transverse/short oblique) Less than 30 degrees obliquity |
| B | Beaking of lateral cortex Periosteal stress reaction |
Hook:ASBMR = American Society for Bone and Mineral Research - use their initials for criteria
BISPHOSPHONATE - RBISPHOSPHONATE - Risk Factors
| B | Bisphosphonate duration greater than 5 years Most important risk factor |
| I | Increased age Older patients at higher risk |
| S | Steroid use (glucocorticoids) Independent risk factor |
| P | Proton pump inhibitors May increase risk |
| H | Hip geometry (varus) Lateral cortex stress concentration |
| O | Other antiresorptives (denosumab) Same mechanism |
| S | South Asian/East Asian ethnicity Higher incidence |
| P | Prior fracture contralateral High risk for bilateral |
| H | Hypophosphatasia Rare but important differential |
| O | Osteoporosis severity Underlying bone quality |
| N | Nutritional deficiencies (vitamin D, calcium) Impaired healing |
| A | Associated rheumatoid arthritis Disease and treatment effects |
| T | Thigh bowing (femoral varus) Mechanical stress concentration |
| E | Estrogen receptor status Hormonal factors |
| B | Bisphosphonate duration greater than 5 years Most important risk factor | H | Hip geometry (varus) Lateral cortex stress concentration | H | Hypophosphatasia Rare but important differential | T | Thigh bowing (femoral varus) Mechanical stress concentration |
| I | Increased age Older patients at higher risk | O | Other antiresorptives (denosumab) Same mechanism | O | Osteoporosis severity Underlying bone quality | E | Estrogen receptor status Hormonal factors |
| S | Steroid use (glucocorticoids) Independent risk factor | S | South Asian/East Asian ethnicity Higher incidence | N | Nutritional deficiencies (vitamin D, calcium) Impaired healing | ||
| P | Proton pump inhibitors May increase risk | P | Prior fracture contralateral High risk for bilateral | A | Associated rheumatoid arthritis Disease and treatment effects |
Hook:The drug name reminds you of risk factors - duration is key
IM NNAIL - Why IM Nail Preferred
| N | Neutralizes bending forces Load-sharing device |
| A | Allows prophylactic fixation contralateral Same anesthetic |
| I | Intramedullary location Protects entire femur |
| L | Less stress concentration No plate end stress riser |
| N | Neutralizes bending forces Load-sharing device | I | Intramedullary location Protects entire femur |
| A | Allows prophylactic fixation contralateral Same anesthetic | L | Less stress concentration No plate end stress riser |
Hook:NAIL is the answer for atypical femoral fractures
THIGH - PTHIGH - Prodromal Symptoms
| T | Thigh pain (anterior or lateral) May precede fracture by months |
| H | History of bisphosphonate use Duration is key |
| I | Investigate with imaging X-ray then MRI |
| G | Get contralateral films Check for bilateral |
| H | High suspicion = prophylactic treatment Consider fixation |
| T | Thigh pain (anterior or lateral) May precede fracture by months | G | Get contralateral films Check for bilateral |
| H | History of bisphosphonate use Duration is key | H | High suspicion = prophylactic treatment Consider fixation |
| I | Investigate with imaging X-ray then MRI |
Hook:THIGH pain in bisphosphonate users should raise suspicion
Overview and Epidemiology
Atypical femoral fractures (AFFs) are stress fractures of the femoral shaft associated with prolonged antiresorptive therapy, particularly bisphosphonates. They have distinct clinical and radiographic features.
Historical context:
- First reports emerged in 2005-2007
- ASBMR Task Force criteria established 2010, revised 2013
- Led to "drug holiday" concept for long-term bisphosphonate users
Risk-Benefit Context
Despite concerns about AFFs, bisphosphonates prevent far more fractures than they cause. The incidence of AFF is approximately 3-10 per 10,000 patient-years, while bisphosphonates prevent approximately 300 hip fractures per 10,000 patient-years. The risk-benefit still strongly favors treatment in most osteoporotic patients.
Epidemiology:
- Incidence: 3-10 per 10,000 patient-years (increases with duration)
- Female predominance (reflects bisphosphonate use patterns)
- Mean age 65-75 years
- Asian ethnicity: higher risk
- Risk increases exponentially after 5+ years of bisphosphonate use
Risk factors:
- Duration of bisphosphonate use (most important - risk doubles after 5 years)
- Glucocorticoid use
- Asian ethnicity
- Femoral bowing (varus geometry)
- Rheumatoid arthritis
- Prior contralateral AFF
- Vitamin D deficiency
Anatomy and Pathophysiology
Location of atypical fractures:
AFFs occur in specific locations:
- Subtrochanteric region: 5cm distal to lesser trochanter
- Femoral shaft (diaphysis): To supracondylar flare
These locations correlate with areas of maximum tensile stress on the lateral cortex during gait.
Pathophysiology:
How bisphosphonates contribute to AFFs:
-
Suppressed bone turnover:
- Bisphosphonates inhibit osteoclast activity
- Bone remodeling is suppressed
- Microdamage accumulates without repair
-
Altered bone quality:
- Increased mineralization over time
- More homogeneous bone matrix
- Reduced ability to absorb energy (more brittle)
-
Stress fracture progression:
- Microcracks develop in lateral cortex
- Unable to heal due to suppressed turnover
- Progress to complete fracture
The lateral cortex is under maximum tension during weight-bearing, making it vulnerable to stress fracture development.
Classification - ASBMR Criteria
ASBMR 2013 Revised Major Criteria
To diagnose an atypical femoral fracture, 4 of 5 major criteria must be present:
| Criterion | Description | Key Points |
|---|---|---|
| 1. Location | Subtrochanteric or diaphyseal | Distal to lesser trochanter to supracondylar |
| 2. Pattern | Transverse or short oblique | Less than 30 degrees from horizontal |
| 3. Trauma | Minimal or no trauma | Fall from standing or less, no trauma |
| 4. Comminution | Non-comminuted or minimal | Simple fracture pattern |
| 5. Lateral cortex | Localized periosteal/endosteal reaction | Cortical thickening, beaking |
Lateral Beaking
Lateral cortex beaking is the pathognomonic feature. It represents the stress reaction where the fracture initiates. On X-ray, look for localized cortical thickening with a transverse lucent line.

Clinical Presentation and Assessment
History:
- Duration and type of bisphosphonate/antiresorptive therapy
- Prodromal thigh or groin pain (present in 70%)
- Mechanism of fracture (usually minimal trauma)
- Previous contralateral symptoms or fracture
- Osteoporosis treatment history
- Glucocorticoid use
Prodromal symptoms:
Prodromal Symptoms and Findings
| Feature | Characteristic | Clinical Significance |
|---|---|---|
| Thigh pain | Anterior or lateral thigh | May precede complete fracture by weeks to months |
| Pain with activity | Worse with weight bearing | Typical stress fracture behavior |
| Dull ache at rest | May have night pain | Indicates progressive stress reaction |
| Bilateral symptoms | 28% have bilateral involvement | Always image contralateral femur |
Physical examination (complete fracture):
- Shortened, externally rotated limb
- Thigh swelling and deformity
- Unable to bear weight
- Neurovascular examination (usually intact)
- Skin assessment for open injury
Physical examination (incomplete fracture):
- May have normal appearance
- Point tenderness over lateral thigh
- Pain with weight bearing
- Full range of hip motion usually preserved
Prodromal Pain
70% of patients with complete AFFs report prodromal thigh pain for weeks to months beforehand. This represents a missed opportunity for intervention. Any patient on long-term bisphosphonates with thigh pain should have imaging to rule out stress fracture.
Investigations
Radiographic assessment:
Plain X-rays (AP and lateral femur):
- Full-length femur views essential
- Look for lateral cortex beaking/thickening
- Transverse fracture line orientation
- Check for contralateral changes (bilateral imaging mandatory)
Key X-ray findings:
| Finding | Description | Significance |
|---|---|---|
| Lateral beaking | Localized cortical thickening | Pathognomonic stress reaction |
| Transverse lucency | Crack in lateral cortex | Incomplete fracture |
| Complete fracture | Transverse pattern, minimal comminution | Meets ASBMR criteria |
| Medial spike | Medial cortex beak on complete fracture | Common finding |
Full-Length Films
Always obtain full-length femur X-rays. This allows assessment of the entire femur for stress reactions and helps plan surgical fixation (nail length, starting point).
Additional imaging:
MRI (if X-ray inconclusive):
- Bone marrow edema at stress reaction site
- Fracture line may be visible before X-ray changes
- Useful for early/incomplete fractures
Bone scan:
- Hot spot at stress fracture site
- Less specific than MRI
- Can assess bilateral involvement
CT scan:
- Better cortical detail than X-ray
- Can show early cortical changes
- Helpful for surgical planning
Laboratory investigations:
- Vitamin D level (deficiency common, affects healing)
- Calcium, phosphate
- Alkaline phosphatase (low in hypophosphatasia)
- PTH if secondary hyperparathyroidism suspected
- Bone turnover markers (research interest)
Differential diagnosis:
Differential Diagnosis of a Subtrochanteric / Diaphyseal Femoral Fracture
| Condition | Typical Features | Key Distinguishing Points |
|---|---|---|
| Atypical femoral fracture (AFF) | Transverse/short-oblique lateral-origin fracture, minimal trauma, lateral cortex beaking | Long-term antiresorptive use, non-comminuted, prodromal thigh pain, often bilateral |
| Typical osteoporotic subtrochanteric fracture | Spiral or comminuted, low bone density | High(er) energy or comminuted pattern, no lateral beaking, no defining antiresorptive link |
| Pathological / metastatic fracture | Lytic or destructive lesion at fracture site | Visible bone destruction, known malignancy, soft-tissue mass; biopsy/staging if uncertain |
| Ordinary (non-AFF) stress fracture | Athletes, military recruits, abrupt training change | No antiresorptive history; commonly medial/compression side rather than lateral tension cortex |
| Hypophosphatasia / osteomalacia (Looser zones) | Pseudofractures, low alkaline phosphatase (hypophosphatasia) | Low ALP, characteristic metabolic bone disease pattern, may mimic incomplete AFF |
| Periprosthetic / peri-implant fracture | Fracture at stem or plate tip stress riser | Implant in situ; manage as periprosthetic - but AFF pattern may coexist in antiresorptive users |
Peritrochanteric Excluded
Peritrochanteric fractures (intertrochanteric and femoral neck) are NOT atypical femoral fractures, even in bisphosphonate users. The ASBMR criteria specifically exclude the peritrochanteric region.
Management

Surgical fixation is required for all complete AFFs.
Preferred fixation: Intramedullary nail
- Cephalomedullary nail (e.g., gamma nail, PFNA)
- Provides load-sharing fixation
- Protects entire femur
- Allows immediate weight bearing (depending on fixation)
- Enables bilateral fixation at same sitting
Surgical considerations:
- Entry point: piriformis or trochanteric entry based on nail design
- Ensure good distal locking
- Consider supplementary fixation if comminuted
- Assess and address contralateral femur
Avoid Lateral Plate Alone
Lateral plate fixation alone should be avoided for atypical fractures. The plate creates a stress riser at its ends, and the abnormal bone quality may predispose to failure. IM nail is preferred. If plate is used, protect entire femur.
Surgical Technique


Patient positioning:
- Supine on fracture table (radiolucent)
- Boot attached with traction
- Contralateral leg in lithotomy or extended
- C-arm access for AP and lateral views
Reduction:
- Traction and internal rotation typically reduces
- May need external reduction aids if shortening/rotation
- Varus tendency common - ensure proper alignment
- Confirm reduction on fluoroscopy before nailing
Key reduction considerations:
- Atypical fractures often have sharp transverse edges
- May need to open and reduce if closed reduction fails
- Avoid excessive manipulation (bone quality poor)
Proper positioning and reduction are essential before proceeding with nailing.
Complications
Complications of Atypical Femoral Fractures
| Complication | Incidence | Prevention/Management |
|---|---|---|
| Delayed union/nonunion | 20-30% | Teriparatide, revision surgery, bone graft |
| Contralateral fracture | 28% overall | Prophylactic fixation, imaging surveillance |
| Refracture | 5-10% | Long nail, protect entire femur |
| Implant failure | Variable | Adequate fixation, consider bone quality |
| Thigh pain (persistent) | Common | May relate to implant, bone healing, or new stress reaction |
| Malalignment | Variable | Careful intraoperative assessment, long nail |
Delayed union and nonunion:
- Higher rate than typical femoral fractures (20-30%)
- Related to suppressed bone turnover
- Consider teriparatide to stimulate healing
- May need revision with bone grafting
- Endocrinology involvement for optimization
Contralateral fracture:
- 28% have bilateral involvement
- May present simultaneously or sequentially
- Emphasizes need for contralateral imaging
- Prophylactic fixation if incomplete fracture identified
Healing Challenges
AFFs have higher rates of delayed union and nonunion (20-30%) compared to typical femoral shaft fractures. This is due to the underlying suppressed bone turnover from bisphosphonate use. Teriparatide may help stimulate healing.
Postoperative Care and Rehabilitation
Postoperative protocol:
- Weight bearing as tolerated (typically)
- DVT prophylaxis
- Pain management
- Early mobilization with physiotherapy
- Wound care
- Progressive ambulation
- Discharge home when safe
- Outpatient physiotherapy
- Monitor wound healing
- X-ray at 6 weeks
- Continued strengthening
- Serial X-rays to monitor healing
- Watch for delayed union
- May require extended time to unite
- Consider teriparatide if delayed
- Ongoing healing assessment
- May take 6-12 months to fully unite
- Address bone health
- Endocrinology referral for osteoporosis management
- Drug holiday discussion
Key rehabilitation principles:
- Early weight bearing with IM nail
- Balance mobility with healing monitoring
- Extended healing time expected
- Address falls risk
- Comprehensive bone health management
Bone health management:
- Stop bisphosphonate (drug holiday)
- Calcium 1000-1200mg/day
- Vitamin D to normalize levels (target greater than 50nmol/L)
- Refer to endocrinology/bone specialist
- Consider teriparatide if delayed union
- Fracture liaison service involvement
Outcomes and Prognosis
Healing outcomes:
| Factor | Impact on Outcome |
|---|---|
| Bisphosphonate duration | Longer duration associated with slower healing |
| Nail vs plate | Nail has better outcomes, fewer complications |
| Teriparatide use | May accelerate healing |
| Vitamin D status | Deficiency delays healing |
| Smoking | Delays healing |
| Contralateral fracture | Increases morbidity |
Functional outcomes:
- Most patients return to pre-injury function
- Some persistent thigh discomfort common
- Hardware removal rarely needed
- Falls prevention important to prevent contralateral fracture
Long-term Considerations
After AFF, patients require ongoing bone health management. This includes drug holiday from bisphosphonates, consideration of alternative treatments (teriparatide), optimization of calcium/vitamin D, and surveillance for contralateral involvement. Fracture liaison service involvement is recommended.
Evidence Base
- Revised case definition: 5 major and 4 minor features, with 4 of 5 major features required for diagnosis. The periosteal/endosteal lateral cortex stress reaction was upgraded from a minor to a major feature, and disease/drug associations were removed from the case definition. AFFs are characterised as stress or insufficiency fractures. Absolute risk on bisphosphonates is low (3.2 to 50 per 100,000 person-years), rising to approximately 100 per 100,000 person-years with long-term use.
- Adjusted hazard ratio for AFF rose with bisphosphonate duration: 8.86 at 3 to less than 5 years and 43.51 at 8 or more years (versus less than 3 months). Risk fell rapidly after discontinuation. Asian women had higher risk than White women (HR 4.84). After 3 years of treatment in White women, 149 hip fractures were prevented for every 2 bisphosphonate-associated AFFs, versus 91 hip fractures prevented for 8 AFFs in Asian women.
- In 1.8 million patients, age-adjusted AFF incidence rose from 1.78 per 100,000 person-years at 0.1 to 1.9 years of bisphosphonate exposure to 113.1 per 100,000 person-years at 8 to 9.9 years. Of 142 atypical fractures, 128 had bisphosphonate exposure (mean 5.5 years).
- Nationwide cohort: age-adjusted relative risk of AFF with bisphosphonate use was 47.3, but the absolute increase was only 5 cases per 10,000 patient-years. Risk diminished by approximately 70% per year after drug withdrawal.
- Among 48,390 women starting oral bisphosphonates, AFF rate was 8-fold higher in Asian than White women (64.2 versus 7.6 per 100,000 person-years; age-adjusted HR 8.5, reduced to 6.6 after adjusting for bisphosphonate duration).
- After 5 years of oral or 3 years of intravenous bisphosphonate, reassess fracture risk. High-risk patients (low hip T-score, prior fracture, fracture on therapy) may continue to 10 years oral or 6 years IV. For patients no longer at high risk, a drug holiday of 2 to 3 years can be considered. AFF risk clearly rises with treatment duration but is outweighed by vertebral fracture reduction in high-risk patients.
- In 33 patients (41 complete AFFs, mean 8.8 years of bisphosphonate use) treated with intramedullary nailing, 98% were radiographically healed by 12 months although healing was delayed, particularly when malaligned. Patients reported a mean of 6 months of prodromal pain; 64% returned to baseline function within 1 year.
Clinical Decision Scenarios
Use these scenarios to practise clinical reasoning and management decisions
Scenario 1: Classic Atypical Femoral Fracture
"A 72-year-old woman on alendronate for 8 years presents after a fall from standing. X-rays show a transverse subtrochanteric fracture with minimal comminution and lateral cortex thickening. What is your diagnosis and management?"
Scenario 2: Prodromal Thigh Pain
"A 68-year-old woman on denosumab for 4 years presents with 3 months of left thigh pain. X-rays show localized lateral cortex thickening in the subtrochanteric region with a faint transverse lucency. She can walk with a limp. What is your management?"
Scenario 3: Nonunion of Atypical Fracture
"A patient had IM nailing of an atypical femoral fracture 9 months ago. She has persistent thigh pain. X-rays show no callus bridging and a persistent fracture line. What is your approach?"
MCQ Practice Points
Definition Question
Q: How many of the ASBMR major criteria must be present to diagnose an atypical femoral fracture? A: 4 of 5 major criteria must be present: subtrochanteric/diaphyseal location, transverse or short oblique pattern, minimal/no trauma, non-comminuted or minimal comminution, lateral cortex beaking.
Risk Factor Question
Q: What is the most important risk factor for atypical femoral fractures? A: Duration of bisphosphonate use. Risk increases exponentially after 5 years of use, with risk doubling approximately every 2 years of continued use.
Clinical Question
Q: What percentage of patients have prodromal symptoms before a complete atypical femoral fracture? A: 70% of patients report thigh or groin pain for weeks to months before the complete fracture. This represents an opportunity for early detection and prophylactic treatment.
Fixation Question
Q: What is the preferred fixation for atypical femoral fractures and why? A: Intramedullary nail is preferred because it is load-sharing (protects abnormal bone), protects the entire femur, and allows prophylactic fixation of the contralateral femur. Lateral plate alone is associated with higher failure rates.
Bilateral Question
Q: What percentage of patients with atypical femoral fracture have bilateral involvement? A: 28% have bilateral involvement. This is why imaging of the contralateral femur is mandatory, and prophylactic fixation should be considered if incomplete fracture is identified.
Guidelines, Registries & Global Practice
Global epidemiology (PubMed-verified): The absolute risk of atypical femoral fracture (AFF) in patients on bisphosphonates is consistently low across registries, while the relative risk is high and strongly duration-dependent. Asian ethnicity is a striking, duration-independent risk factor reported across multiple health systems.
| Population / Source | AFF incidence or risk | Notes |
|---|---|---|
| Sweden (national, Schilcher 2011) | Absolute increase 5 per 10,000 patient-years; RR 47.3 | Risk falls ~70% per year after withdrawal |
| Kaiser S. California (Dell 2012) | 1.78 → 113.1 per 100,000/yr (0–2 vs 8–10 yr use) | Incidence rises sharply with duration |
| Kaiser (Black 2020) | HR 8.86 at 3–5 yr → 43.51 at greater than 8 yr | Asian vs White HR 4.84 |
| Kaiser N. California (Lo 2016) | Asian 64.2 vs White 7.6 per 100,000/yr (8-fold) | Adjusted HR 8.5 |
Side-by-side guidance from major bodies:
| Body (Region) | Core guidance on AFF / long-term antiresorptives | Evidence level |
|---|---|---|
| ASBMR Task Force (international) | 5 major / 4 minor criteria; reassess after 5 yr oral or 3 yr IV; drug holiday 2–3 yr if no longer high-risk; continue to 10 yr (oral)/6 yr (IV) if high-risk | Expert consensus on cohort data |
| AAOS / OTA (USA) | IM nailing preferred for complete AFF; image and consider prophylactic fixation of contralateral femur; multidisciplinary bone-health pathway | Consensus / cohort |
| NICE & NOGG (UK) | Review bisphosphonate need after 5 years (3 yr for IV zoledronate); reassess fracture risk; consider holiday in lower-risk patients | Guideline |
| Royal Osteoporosis Society (UK) | Investigate thigh/groin pain in long-term users with full-length femoral imaging; stop antiresorptive if AFF confirmed | Guideline |
| RACGP / Healthy Bones Australia | Reassess after 5 years oral / 3 years IV; fracture liaison services for secondary prevention | Guideline |
Registry and large-cohort evidence: The dominant data come from integrated-care cohorts (Kaiser Permanente) and national registries (Sweden) rather than arthroplasty-style implant registries, because AFF is a pharmacovigilance rather than a device outcome. These consistently show the same message: net benefit of treatment is large in lower-risk (often White) populations and attenuated, though usually still favourable, in Asian patients.
Practice variation: Concern about AFF has been associated with a substantial fall in bisphosphonate prescribing and a possible rise in hip-fracture incidence in some health systems (Black 2020). Drug-holiday thresholds, the weight given to Asian ethnicity, and the threshold for prophylactic contralateral nailing all vary between centres.
Australian context: Bisphosphonates, denosumab and teriparatide are available via the PBS for osteoporosis (teriparatide for severe disease/high fracture risk). Australia's relatively high proportion of patients of Asian background makes ethnicity-specific counselling particularly relevant, and fracture liaison services are central to secondary prevention.
Exam Context
In the Orthopaedic exam, be prepared to discuss the ASBMR criteria (know all 5 major criteria, with lateral cortex beaking now a MAJOR feature), the importance of full-length imaging of both femora, and the rationale for IM nail fixation. Understand drug-holiday concepts (reassess after 5 yr oral / 3 yr IV) and the role of teriparatide in delayed healing.
ATYPICAL FEMORAL FRACTURES
Clinical summary
ASBMR MAJOR CRITERIA (4 of 5 Required)
- •1. Location: Subtrochanteric or femoral shaft
- •2. Pattern: Transverse or short oblique (less than 30 degrees)
- •3. Trauma: Minimal or no trauma
- •4. Comminution: Non-comminuted or minimal
- •5. Lateral cortex: Localized periosteal/endosteal reaction (beaking)
KEY RISK FACTORS
- •Bisphosphonate duration greater than 5 years (most important)
- •Glucocorticoid use
- •Asian ethnicity
- •Femoral varus/bowing
- •Prior contralateral AFF
SURGICAL MANAGEMENT
- •IM nail preferred (load-sharing, protects whole femur)
- •Avoid lateral plate alone (stress riser)
- •Always image contralateral (28% bilateral)
- •Prophylactic nail if incomplete fracture
- •Consider bilateral fixation at same sitting
POST-FRACTURE BONE HEALTH
- •Stop bisphosphonate (drug holiday)
- •Optimize vitamin D (target greater than 50nmol/L)
- •Calcium supplementation
- •Consider teriparatide if delayed union
- •Endocrinology referral
COMPLICATIONS
- •Delayed union/nonunion (20-30%)
- •Contralateral fracture (28%)
- •Refracture
- •Prolonged healing time
TRAPS AND PEARLS
- •70% have prodromal thigh pain - investigate!
- •Risk-benefit still favors bisphosphonates overall
- •Lateral beaking is pathognomonic
- •Peritrochanteric fractures are NOT atypical
- •Expect longer healing than typical fractures
